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ABSTRACT 
 
We? sought? to? identify? the? impacts? of? Friedreich’s? ataxia? (FRDA)? on? cardiomyocytes.? FRDA? is? an? autosomal
recessive? degenerative? condition? with? neuronal? and? non?neuronal? manifestations,? the? latter? including
progressive?cardiomyopathy?of?the?left?ventricle,?the?leading?cause?of?death?in?FRDA.?Little?is?known?about?the
cellular? pathogenesis? of? FRDA? in? cardiomyocytes.? Induced? pluripotent? stem? cells? (iPSCs)?were? derived? from
three?FRDA? individuals?with?characterized?GAA? repeats.?The?cells?were?differentiated? into?cardiomyocytes? to
assess? phenotypes.? FRDA? iPSC?? cardiomyocytes? retained? low? levels? of? FRATAXIN? (FXN)?mRNA? and? protein.
Electrophysiology?revealed?an?increased?variation?of?FRDA??cardiomyocyte?beating?rates?which?was?prevented
by?addition?of?nifedipine,?suggestive?of?a?calcium?handling?deficiency.?Finally,?calcium? imaging?was?performed
and?we? identified?small?amplitude,?diastolic?and?systolic?calcium?transients?confirming?a?deficiency? in?calcium
handling.?We?defined?a?robust?FRDA?cardiac?specific?electrophysiological?profile?in?patient?derived?iPSCs?which
could? be? used? for? high? throughput? compound? screening.? This? cell?specific? signature? will? contribute? to? the
identification?and?screening?of?novel?treatments?for?this?life?threatening?disease. 
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INTRODUCTION 
 
FRDA is an autosomal recessive degenerative condition 
with neuronal and non-neuronal manifestations [1]. 
Cardiomyopathy is detected in two thirds of individuals 
with FRDA [2-4]. Individuals with FRDA generally 
present with progressive cardiomyopathy of the left 
ventricle, which is the leading cause of death in FRDA 
due to arrhythmias and/or heart failure [5, 6]. Little is 
known of the cellular impacts of FRDA in the heart, but 
cardiomyocyte necrosis and cellular fibrosis have been 
identified [6, 7]. Systolic function generally remains 
normal until late in disease progression [8]. In 
approximately 96% of affected individuals, FRDA is 
due to homozygosity for an unstable expanded GAA 
repeat mutation in the first intron of FXN resulting in 
reduced expression of the nuclear-encoded mito-
chondrial protein FXN [9-11]. Despite the identification 
of FXN, its precise role in FRDA pathogenesis remains 
elusive and remarkably little is known about the 
molecular pathology of cardiomyocytes in FRDA [12]. 
 
Human iPSCs [13-15] have been derived from 
individuals with FRDA [12, 16-19]. Morphological 
abnormalities and a disorganized mitochondrial network 
in iPSC-derived- cardiomyocytes have been identified 
[16, 19]. There are no abnormalities under basal 
conditions, when cultivated in the presence of iron, 
cellular hypertrophy occurs  [19]. However, more 
detailed functional studies are needed to characterize the 
cardiomyocytes from FRDA iPSCs. Here, we derived 
FRDA iPSCs to assess the electro-physiological and 
calcium (Ca2+) cycling properties of cardiomyocytes, to 
identify potential mechanisms underlying the cardio-
myopathy observed in FRDA.  
 
RESULTS 
 
Generation of three FRDA-iPSC lines and 
differentiation into cardiomyocytes 
 
We generated FRDA-iPSC lines from three individuals 
with different GAA length repeat numbers (Table 1). 
We also collected data regarding disease severity as 
measured by the Friedreich Ataxia Rating Scale (FARS) 
[20]. The FARS is scored out of 167, a higher score 
indicating greater disease severity.  Clinical parameters 
of individuals from whom the lines were derived are as 
follows: FA6 (female; GAA1 1077, GAA2 1077; FARS 
score 96.5); FA8 (male; GAA1 476, GAA2 545; FARS 
score 64.5); FA9 (male; GAA1 733, GAA2 943; FARS 
score 118). The individuals with FRDA from which 
iPSCs were derived presented with the following 
cardiac phenotypes: FA6: normal ejection fraction 
(55%), normal ventricular wall thickness, mildly dilated 
left atrium (mild cardiomyopathy); FA8: normal 
ejection fraction (60%), moderate increase in relative 
wall thickness (RWT), severe dilatation of the left 
atrium (typical FRDA cardiomyopathy) and FA9: low 
normal ejection fraction (50%), increased RWT, 
borderline increase in left atrial size (typical FRDA 
cardiomyopathy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure? 1.? Generation? of? iPSC? lines? from? FRDA?patients.
Immunostaining?of?FA6?CL1?(A,?D),?CL2?(B,?E),?CL3?(C,?F)?for?OCT4?(A?
C)?and?TRA?1?60?(D?F);?FA8?CL1?(G,?J),?CL2?(H,?K),?CL3?(I,?L)?for?OCT4
(G?I)?and?TRA?1?60? (J?L);?FA9?CL1? (M,?P),?CL2? (N,?Q),?CL3? (O,?R)? for
OCT4? (M?O)? and? TRA?1?60? (P?R).? (S)? Negative? isotype.? Cells? were
counterstained?with?DAPI?(blue).?Scale?bars:?50??m.?
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We used nucleofection to deliver episomal vectors 
containing OCT4, SOX2, KLF4, L-MYC, LIN28, 
shRNA against p53 and eGFP into fibroblasts. 
Pluripotent clones were expanded and three clones 
were selected for each patient (CL1-3). All clones 
expressed the pluripotency markers OCT4 and TRA-1-
60 (Fig.1A-S). The intron 1 FXN GAA expansions 
were measured for all fibroblasts and iPSC clones 
(Table 1, Suppl. Fig. 1). As reported for other FRDA 
iPSCs [16-18], we observed similar repeat numbers  as  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
well as contractions and expansions for all lines, with 
slight variations between clones of the same line 
(Table 1). Importantly, the patient-derived iPSC lines 
each maintained the reduced FXN mRNA expression 
that is characteristic of FRDA, when compared to 
control cells (Fig. 2A). The iPSCs were karyotypically 
normal (data not shown), and pluripotent, being able to 
differentiate into cells of the three germ layers as 
assessed by embryoid body (EB) formation (Suppl. 
Fig. 2-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure?2.?FRDA?iPSCs?and???cardiomyocytes?retain?low?levels?of?FXN?and?are?mainly?of?ventricular?phenotype.?(A,?B)?qPCR
and?(C)?dipstick?analysis?showing?low?levels?of?FXN?mRNA?(A,?B)?and?protein?(C)?in?undifferentiated?cells?(A)?and?their?cardiac?derivatives
(B,?C).?Significance?was?assessed?by?comparing?FRDA?iPSCs?to?undifferentiated?H9?controls?(A)?or?FRDA?iPSC?derived?cardiomyocytes?to?H9
derived?cardiomyocyte?controls?(B,?C).?One?way?ANOVA?followed?by?Bonferroni’s?multiple?comparison?test,?**?p<0.01?,?****?p<?0.0001.
(D)?qPCR?analysis?of?cardiomyocytes?showing?significantly?higher?expression?of?MYL2?than?MYL7?across?all?cell?lines?(p<0.05,?paired?t?test).
(A?D)?Data?are?mean?±?SEM?of?combined?clones?or?3?individual?experiments,?normalized?to?ACTB?and?relative?to?undifferentiated?cells?(A,
B,?D)?or?normalized?to?the?control?line?cardiomyocyte?(C).?(E?G)?Representative?images?of?FA6??cardiomyocytes?(E),?FA8??cardiomyocytes
(F)?and?FA9??cardiomyocytes?(G)?for?MYL2/MLC2v?(green),?MYL7/MLC2a?(red,?weak?or?absent)?and?counterstained?with?DAPI?(blue).?
 
Table?1.?GAA?repeats?(GAA1/GAA2).?GAA1:?smaller?allele?repeats;?GAA2:?longer?allele?repeats.?F:?
Female,?M:?Male.?FARS:?Friedreich?Ataxia?Rating?Scale. 
 FA6 (F, FARS: 96.5) FA8 (M, FARS: 64.5) FA9 (M, FARS:118) 
Patient, predicted 1077/1077 476/545 733/943 
Fibroblasts 854/247 481/576 788/109 
CL1 893/281 579 963 
CL2 887/273 593/323 980/383 
CL3 980/294 576/315 991 
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All lines were differentiated into cardiomyocytes using 
a small-molecule based approach [21]. In basal 
conditions, FRDA- cardiomyocytes were not hyper-
trophic, as assessed by the absence of nuclear 
localisation of NFATC4 (Suppl. Fig. 5), a nuclear 
translocation known to be a marker of hypertrophy [22, 
23]. The FRDA- cardiomyocytes retained low levels of 
FXN mRNA and protein (Fig. 2B, C). Phenotypes were 
assessed at day 35. At this stage, transcripts of MYL2 
were significantly higher than MYL7 across all cell lines 
(Fig. 2D). The cardiomyocytes expressed MYL2/MLC2v 
protein and MYL7/MLC2a was rarely observed (Fig. 
2E-G). Taken together, these data suggest a ventricular 
phenotype in the cardiomyocytes that were generated 
with minimal atrial cardiomyocytes for all lines (Fig. 
2D-G) [19, 24].   
 
FRDA-iPSC-derived cardiomyocytes display 
phenotypic abnormalities 
 
The Multi Electrode Array (MEA) revealed electro-
physiological anomalies in the different FRDA lines, 
with consistent effects in all three clones of all FRDA 
lines. All FRDA lines  showed  similar  basal  beat  rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(30-40 beat per minute, Fig. 3A) which were slower 
than control cardiomyocytes. All lines showed similar 
corrected extracellular field potential durations (cFPD, 
Fig. 3B). We assessed the root of the mean of the sum 
of the square of the difference in the RR interval 
(RMSSD), that measures the variation in a consecutive 
series of intervals between field potentials (Fig. 3C, D). 
FRDA-iPSC-derived cardiomyocytes showed signi-
ficantly increased RMSSD under basal conditions and 
when treated with isoprenaline (10-6 M, Fig. 3C, D). 
Elevated RMSSD in cultured cardiomyocytes, including 
those derived from PSCs, is indicative of Ca2+ handling 
abnormalities. When FRDA- cardiomyocytes were 
examined under basal conditions or following treatment 
with isoprenaline, application of nifedipine (10-8 M), 
which partially blocks L-type Ca2+ channels, prevented 
an increase in RMSSD, thus confirming that Ca2+ is 
responsible for the abnormal beat rate variability in line 
with other studies on PSC-derived cardiomyocytes. In 
contrast, blocking K+ channels with TEA (10-8 M) did 
not modify the effect of isoprenaline, with an increase 
in RMSSD and in cFPD (data not shown). Altogether, 
these data suggest that FRDA- cardiomyocytes display 
a significant increase  in  beat  rate  variability,  demons- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure?3.?Assessment?of?phenotypes? in?FRDA? iPSC?derived?cardiomyocytes.? (A)?Beating? rates? (beats?per?minute,?BPM),? (B)
corrected?extracellular?field?potential?durations?(cFPD)?and?(C,?D)?the?root?of?the?mean?of?the?sum?of?the?square?of?the?difference?in?the
RR? interval? (RMSSD)? (ms).? Data? shows? RMSSD? at? basal? (C)? and? 10?6M? (D)? isoprenaline? ±? nifedipine? (NIF).? (E)? Representative? Ca2+
transients.? (F)?Diastolic,? (G)? systolic? and? (H)? amplitude? Ca2+? in? Control? and? FRDA?? cardiomyocytes.? (A?D)?Data? are?mean? ±? SEM? of
combined?values?of?3?clones?of?each?line?(n=3?per?line)?and?as?a?pool?of?all?3?clones?of?all?FRDA?lines?(n=9?FRDA?independent?samples)
and?control?cardiomyocytes?(n=6).?(F?H)?Data?are?mean?±?SEM?of?combined?values?control?cardiomyocytes?(n=5),?of?all?3?clones?of?each
FRDA?line?(n=8?14?per?line)?and?as?a?pool?of?all?3?clones?of?all?FRDA?lines?(n=35?FRDA?independent?samples).?Statistics:?(A?D,?F?H)?One?
way?ANOVA?followed?by?Bonferroni’s?multiple?comparison?test,?*?p<0.05,?**,?p<0.01,?***,?P<0.001.?
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trating a potential for cardiac dysfunction, compared to 
the control cardiomyocytes. These data also suggest that 
impairment in Ca2+ handling is responsible for the 
observed electrophysiological phenotype. This was 
confirmed by assessing Ca2+ transients. In the FRDA-
cardiomyocytes significantly lower diastolic and 
systolic Ca2+ levels and reduced transient amplitude 
signals were observed compared with control cardio-
myocytes (Fig. 3 E-H). Collectively, our data 
demonstrates a Ca2+ handling impairment in the FRDA 
cardiomyocytes. 
 
DISCUSSION 
 
Our data reveal electrophysiological anomalies in 
FRDA iPSC derived - cardiomyocytes, with an increase 
beat rate variability. As partial inhibition of L-type Ca2+ 
channels with nifedipine abolished this electro-
physiological phenotype, it demonstrates that the 
electrophysiological impairment is due to Ca2+ handling 
abnormalities. As cFPD were not increased in the 
FRDA iPSC-derived cardiomyocytes, Ca2+ overload is 
unlikely. This was confirmed with measurement of Ca2+ 
cycling, which identified that FRDA cardiomyocytes 
show low Ca2+ transients. Yet, it is difficult to reconcile 
how the increased beat rate variability is remedied by 
the Ca2+ channel blocker nifedipine, when the Ca2+ 
transients suggest that cytosolic Ca2+ levels were 
already lower than in the controls. It is feasible that in 
the context of mitochondrial dysfunction in FRDA, 
ATP-dependent  ion  channels,  particularly  sarco/endo- 
plasmic reticulum Ca2+-ATPase, may lack the required 
ATP for proper functioning, leading to reduced Ca2+ 
storage in the sarcoplasmic reticulum and therefore 
reduced Ca2+-induced Ca2+ release during an action 
potential. There have been two previous reports 
describing phenotypes in FRDA iPSC-derived cardio-
myocytes, including Ca2+ handling deficiencies, albeit 
in the presence of exogenous iron [19, 24]. Yet, whilst 
iron accumulation is generally regarded as a common 
feature of FRDA pathogenesis, there is scant evidence 
of iron accumulation in the heart [25]. The data reported 
here provide the first demonstration of a phenotypic 
abnormality in cardio-myocytes derived from FRDA-
iPSCs without such artificial iron treatment or external 
stimulus. This suggests that reduced FXN causes 
dysfunction in cardiomyocytes prior to events such as 
accumulation of iron. The establishment of a phenotype, 
itself reversible by selective treatment with nifedipine, 
now forms a platform to screen molecules known to 
modify FXN and directly assess their impact on human 
FRDA- cardio-myocytes, and hence contribute to the 
discovery of specific treatments for FRDA. Indeed, 
cardiomyocytes derived from patient iPSCs show clear 
phenotypic abnormalities, consisting of an increase in 
beat rate variability and reduced Ca2+ transients. 
Although not assessed here, mitochondrial oxidative 
phosphorylation (OXPHOS) deficiencies, which are 
reported in FRDA [26], can reduce mitochondrial Ca2+ 
uptake and ATP production [27, 28]. It has also been 
suggested that mitochondrial OXPHOS defects in 
FRDA could be an indirect consequence of oxidative 
stress [29]. Given the impact of reduced Ca2+ levels on 
mitochondrial function, our data suggests that Ca2+ 
handling defects could also contribute to the perceived 
OXPHOS deficiencies. Treatment of FRDA- 
cardiomyocytes with nifedipine improved phenotypes 
detected by MEA.  Whilst it may seem contradictory 
that partially inhibiting L-type Ca2+ channels improves 
cardio-myocytes with low Ca2+ levels, it is possible that 
nifedipine is acting on other Ca2+ channels 
independently [30]. This may either mask or restore the 
Ca2+ levels in the cardiomyocytes [31].  Further in-
depth investigations directed at Ca2+ handling 
machinery of FRDA iPSC-derived cardiomyocytes 
should unravel the mechanisms behind these pheno-
types and identify therapeutic targets. 
 
It might be counterintuitive to relate an increased 
RMSSD in cultured cardiomyocytes to patient pheno-
types. Indeed, patients presenting with cardiomyopathy, 
including FRDA patients, demonstrate reduced heart 
rate variability compared to healthy individuals [32]. 
However, these measures in patients relate more to the 
function of the autonomic nervous system rather than 
the function of cardiomyocytes. To our knowledge only 
two studies have assessed Ca2+ levels in post-mortem 
FRDA hearts, both describing elevated right ventricle 
Ca2+ levels, and low-to-normal left ventricle levels in 
the earlier report versus somewhat elevated left 
ventricle Ca2+ in a recent report [25, 33]. It is however 
feasible that the FRDA-iPSC derived cardiomyocytes 
are useful in identifying pathophysiology underlying or 
preceding the cardiomyopathy observed in FRDA. 
Importantly, our data clearly indicates that FRDA iPSC- 
derived cardiomyocytes can be used for screening of 
compounds able to alter or reverse phenotypes, in 
human cells, hence providing a novel and unique tool 
for FRDA research.  
 
METHODS 
 
Ethics Committee approvals 
 
All experimental work performed in this study was 
approved by the Human Research Ethics Committees of 
the University of Melbourne (0829937, 0605017, 
1545383, 1545394) meeting the requirements of the 
National Health & Medical Research Council of 
Australia (NHMRC) and conforming to the 
Declarations of Helsinki.  
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Biopsies 
 
The biopsy measured approximately 2–3 mm in 
diameter and was taken via a needle from the inside of 
the forearm by a qualified clinician. The risks 
associated with a skin biopsy are small, however the 
risks of bleeding and infection were minimised through 
careful technique, the use of antiseptics and sterile 
instruments. Minimal pain was experienced at the site 
once the anaesthetic had worn off and none of the 
individuals reported any complications following this 
procedure. 
 
iPSC Generation 
 
iPSCs were generated using skin fibroblasts obtained 
from FRDA (FA6, FA8 and FA9) and control subjects 
over the age of 18 years by an episomal method as 
described previously [34]. Reprogramming was 
performed on passage 8-10 fibroblasts by nucleofection 
with episomal vectors expressing OCT4, SOX2, KLF4, 
L-MYC, LIN28 and shRNA against p53 [35].  
 
Maintenance of pluripotent stem cells (PSCs) and 
cardiomyocyte differentiation 
 
The FRDA-iPSC lines FA6, FA8, FA9 and the control 
human embryonic stem cell (hESC) line H9 (WiCell)   
[36] were maintained in the undifferentiated state using 
TeSR-E8 medium (Stem Cell Tech). H9 was used as a 
control as the line is very well described; H9-derived 
cardiomyo-cytes are structurally and functionally 
similar to iPSC-derived cardiomyocytes [23, 37, 38], 
and have been used as a control for overexpression of 
mutant MYH7 for modelling cardiomyopathy [23]. 
hESCs are known to be molecularly and functionally 
equivalent to iPSCs [39], hence can serve as adequate 
controls to iPSCs. Embryoid bodies (EB) were obtained 
as described [40]. In the functional MEA experiments, 
the control iPSC line, iPSC(Foreskin)-2 [41] was also 
used, in order to ensure that variations observed 
between FRDA iPSCs lines and H9 cells were not 
peculiar to the latter. Differentiation into 
cardiomyocytes was achieved using a small molecule-
based approach, with initial exposure to GSK? 
inhibitors (1 μM BIO, 3.5 μM CHIR99021) for 2 days, 
followed by addition of  XAV939 (2 μM) and KY02111 
(10 μM) from days 3-8, in IMDM containing 4 mM L-
glutamine, 25 mM HEPES, 1% non-essential amino 
acids, 4 mg/mL human albumin, 100 μM 2-
mercaptoethanol, 25 U/mL penicillin, 25 μg/mL 
streptomycin (all from Thermo Fisher Scientific) and 
120 μg/mL L-ascorbic acid sesquimagnesium salt 
(Sigma Aldrich) [21]. Following two weeks of 
differentiation in adherent culture, cells were harvested 
and grown as floating spheres for an additional two 
weeks in cardiac differentiation medium containing 0.4 
mg/mL albumin and 12 μg/mL L-ascorbic acid 
sesquimagnesium salt. For subsequent work, cells were 
dissociated with a protease mixture containing 0.1% 
collagenase I (Wako Pure Chemicals), 0.25% trypsin 
and 1 U/mL DNase I (Thermo Fisher Scientific) in a 
buffer consisting of 116 mM NaCl, 20 mM HEPES, 
12.5 mM NaH2PO4, 5.6 mM glucose, 5.4 mM KCl, 0.8 
mM MgSO4, pH 7.35 (all from Sigma Aldrich). 
Dissociated cardiomyocytes were plated as monolayers 
on laminin- or Matrigel-coated plates or slides in 
albumin- and ascorbic acid-free medium. To assess 
differentiation, we performed qPCR and/or immuno-
staining of the cardiac markers actin alpha cardiac 
muscle 1 (ACTC1), troponin T type 2 (TNNT2), 
troponin I type 3 (TNNI3) and NK2 transcription factor 
related locus 5 (NKX2.5) to assess presence of 
cardiomyocytes, and atrial and ventricular myosin light 
chain 2 (MLC2a/ MLC2v) to assess the proportion of 
atrial and ventricular cardiomyocytes. TNN and ACTC 
staining were also used to assess cardiomyocyte 
morphology. Nuclear factor of activated T cells 4 
(NFATC4) was used to assess the presence of 
hypertrophy in the cardiomyocytes. A visual assessment 
of beating cells further confirmed the cardiac 
phenotype.  
 
Real-time quantitative RT-PCR 
 
Total RNA was extracted from cells using the RNeasy 
Mini Kit (Qiagen, Hilden, Germany), converted to cDNA 
using High Capacity cDNA Reverse Transcriptase Kit 
(Applied Biosystems, Foster City, CA). Q-PCRs were 
carried out using TaqMan Universal master mix and the 
7900HT Fast Real-Time PCR system using TaqMan 
gene expression assay for FXN (Hs00175940_m1), 
MLC2a/MYL7 (Hs01085598_g1), MLC2v/MYL2, 
(Hs00166405_m1), ACTC1 (Hs01109515_m1), TNNT2 
(Hs00165960_m1), TNNI3 (Hs00165957_m1), NKX2.5 
(Hs00231763_m1), Glyceraldehyde 3-phosphate 
dehydrogenase (Human GAPDH, Hs99999905_m1), 
beta-actin (ACTB; Hs99999903_m1) (all from Applied 
Biosystems). The relative quantitation was achieved by 
applying the comparative CT method (??CT) whereby 
the mRNA levels were normalized against the level of 
GAPDH or ACTB and the control group was used as the 
calibrator.  
 
Immunofluorescence 
 
Cells were fixed with 4% paraformaldehyde (PFA) or 
ethanol (OCT-4), blocked in 10% fetal calf serum-PBT, 
and immunostained using the following antibodies: 
mouse anti-OCT3/4 (Santa Cruz Biotechnology), mouse 
anti-TRA-1-60 (Millipore), mouse anti-NESTIN 
(Millipore), rabbit anti-alpha-fetoprotein (AFP, Dako), 
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mouse anti-smooth muscle actin (SMA, R&D systems), 
mouse anti-ACTC1 (Abcam), rabbit anti-NFATc4 
(Santa Cruz), rabbit anti-MYL2 (Proteintech), mouse 
anti-MYL7 (abcam). Cells were then immunostained 
with the appropriate conjugated secondary antibodies 
(Alexa Fluor 568 or 488, Molecular probes-Invitrogen). 
Nuclei were counter-stained with Hoechst-33342 
(Sigma-Aldrich) or DAPI (Invitrogen). Specificity of 
the staining was verified by the absence of staining in 
negative controls consisting of the appropriate negative 
control immunoglobulin fraction (Dako).  
 
GAA expansion analysis 
 
Genomic DNA for GAA expansion analyses was 
extracted from fibroblasts and iPSCs using the QIAamp 
DNA Mini Kit (Qiagen) according to the 
manufacturer’s instructions. The concentration and 
purity of the genomic DNA were assessed using a 
Nanodrop1000 spectrophotometer (Thermo Fisher 
Scientific). The size of the GAA expansion in intron 1 
of the FXN gene was determined by PCR using the 
Expand Long Range dNTPack (Roche, Australia) as 
recommended with 20 ng template DNA, 0.4 ?M of 
EXP-Bam-F 5?AAGGAAGTGGTAGAGGGTGTTTCA 
CGAGGA3? and EXP-Bam-R 5?TTTGGATCCAACTC 
TGCTGACAACCCATGCTGTCCACA3? primers and 
1x Q solution (QIAGEN, Australia). PCR products 
were electrophoresed on a 1% (w/v) agarose, 1x TAE 
gel alongside standard DNA markers (200 bp ladder, 
Promega). Size determination was performed using 
GeneTools software from SynGene, Synoptics (In Vitro 
Technologies). The positive control (BAC clone RP11-
265B8) and non-expanded alleles in the normal range 
yielded an 810 bp fragment. The hESC H9, BG01V 
(ATCC) and the human fibroblast feeders WS1 (ATCC) 
were included as negative controls for FXN expansion. 
 
Dipstick of FXN expression 
 
Dipstick assay for FXN (Mitosciences) was performed 
as per the manufacturer’s instructions [42]. This method 
allows the quantification of FXN by using two specific 
monoclonal antibodies against different antigens of 
FXN, in a sandwich ELISA assay. Briefly, one capture 
antibody bound to a nitrocellulose membrane captures 
FXN, and a detector antibody conjugated to gold 
provides a signal when bound to the complex of capture 
antibody-FXN-detector antibody. Levels of FXN are 
then detected and quantified by an increased signal 
intensity. 
 
Electrophysiological characterization 
 
Electrophysiological measurements of cardiomyocytes 
seeded onto laminin-coated 60 electrodes MEA plates 
were performed by MEA (Multichannel Systems, 
Reutlingen, Germany) as previously described [40]. 
Cells were incubated at 370C in cardiac differentiation 
medium without albumin and ascorbic acid. Basic 
receptor and ion channel function were assessed by 
treatment of cardiomyocytes with nifedipine (inhibitor 
of L-type Ca2+ channel) and isoprenaline (?-adrenergic 
receptor agonist) (Sigma-Aldrich). Extracellular field 
potentials were recorded at baseline and 1 minute after 
addition of drugs. Data were analyzed offline with MC 
Rack version 4.3.5 software for beating rate, inter-beat 
(RR) interval and extracellular field potential duration 
(FPD). RR interval was defined as the time elapsing 
between two consecutive beats, and FPD was defined as 
the time interval between the initial deflection of the 
field potential and the maximal local T wave. To avoid 
the influence of beat frequency on FPD, FPD measure-
ments were normalized (corrected FPD, cFPD) with the 
Bazett’s correction formula: cFPD = FPD/?(RR 
interval) [43]. Data were expressed as percentage 
change from baseline with baseline set to 100%. Root of 
the mean of the sum of the square of the difference in 
the RR interval (RMSSD) was also assessed. 
 
Intracellular Ca2+ and contractility measurements 
 
Intracellular Ca2+ was measured by microfluorimetry 
(Ionoptix MA, USA). Cells were loaded with the Ca2+ 
fluorescent dye FURA-2/AM (5 ?M, 10 min incubation 
at room temperature, Molecular Probes). They were 
placed in a chamber mounted on the stage of a Motec 
AE31 inverted fluorescence microscope immersed in 
medium (IMDM without phenol red, containing 4 mM L-
glutamine, 25 mM HEPES, 1% non-essential amino 
acids, 25 U/mL penicillin and 25 μg/mL streptomycin; 
the total concentration of Ca2+ in the medium was 1.5 
mM), at room temperature and stimulated to contract at 
1Hz. Excitation light at 340 nm and 380 nm was 
provided by a 75-watt xenon lamp and filter wheel. 
Emitted fluorescence (510 nm) was recorded by a 
photomultiplier tube, with the output current converted to 
voltage and digitized for subsequent analysis. Back-
ground correction was undertaken at the completion of 
each cell recording and incorporated into analysis 
protocol. The following Ca2+ parameters were measured: 
diastolic Ca2+, systolic Ca2+, amplitude of the Ca2+ transi-
ent and time constant of decay of the Ca2+ transient (tau). 
 
Statistical analysis 
 
Data are expressed as mean ± standard error of the 
mean (SEM). All statistical analyses and graphical data 
were generated using Graphpad Prism software (v5.04, 
www.graphpad.com). Statistical methods utilized were 
one-way ANOVA followed Tukey’s or Bonferroni’s 
multiple comparisons test and t-test. Statistical 
www.aging?us.com? 1447? AGING 
significance was established as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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SUPPLEMENTARY MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary?Figure?2.?Representative?germ?layer?immunostaining?of?FA6?EBs.?FA6?Clone?1?3
(A?C,?D?F,?G?H)?demonstrate?pluripotency?by?positive?staining?for?markers?of?each?embryonic?germ?layer;
endoderm?(AFP;?A,?D,?G),?mesoderm?(SMA;?B,?E,?H)?and?ectoderm?(nestin;?C,?F,?I).?Scale?bars?=?50??m.?
Supplementary?Figure?1.?GAA?expansion?PCR.?The?size?of?the?GAA?expansion
was?determined?in?control?(H9,?BG01V,?WS1)?and?FRDA?cells?(FA6,?FA8?and?FA9)?by
comparison? to? standard? DNA? markers? (MW).? Genomic? DNA? isolated? from
fibroblasts?(Fibro)?and?iPSC?clones?(CL)?1?3?were?used?in?long?range?PCR?of?the?first
intron?of?FXN.?Non?expanded?alleles?yield?a?product?of?810?bp.?Positive? (Human
embryonic?stem?cell?lines?H9?and?BG01V,?human?fibroblast?WS1,?BACRP11?265B8
DNA? containing? the? FXN? gene,? Control? genomic? (g)DNA? and? FRDA? gDNA)? and
negative?controls?(no?DNA)?were?included.?
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Supplementary?Figure?3.?Representative?germ?layer?immunostaining?of?FA8?EBs.?FA8?Clone?1?3
(A?C,?D?F,?G?H)?demonstrate?pluripotency?by?positive?staining?for?markers?of?each?embryonic?germ?layer;
endoderm?(AFP;?A,?D,?G),?mesoderm?(SMA;?B,?E,?H)?and?ectoderm?(nestin;?C,?F,?I).?Scale?bars?=?50??m. 
Supplementary?Figure?4.?Representative?germ?layer?immunostaining?of?FA9?EBs.?FA9?Clone?1?3
(A?C,?D?F,?G?H)?demonstrate?pluripotency?by?positive?staining?for?markers?of?each?embryonic?germ?layer;
endoderm?(AFP;?A,?D,?G),?mesoderm?(SMA;?B,?E,?H)?and?ectoderm?(nestin;?C,?F,?I).?Scale?bars?=?50??m. 
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Supplementary?Figure?5.?Assessment?of?hypertrophy?in?FRDA?cardiomyocytes.?FA8?cardiomyocytes?35?days?post?
differentiation?untreated?(A?D)?or?treated?with?1μM?isoprenaline?to?induce?hypertrophy?(E?H),?immunostained?for?troponin
(A,?E);?NFATc4? (B,?F),?counterstained?with?DAPI? (C,?G)?and?merged? (D,?H).?Nuclear? localisation?of?NFATc4? is? indicative?of
hypertrophy?and?some?are?illustrated?with?arrows.?Data?presented?on?FA8?cells?are?representative?of?all?cell?lines?tested. 
